Screener
Kymera Therapeutics KYMR Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net loss | $(130,445) | $(142,195) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 34,945 | 29,649 |
| Depreciation and amortization | 4,052 | 4,132 |
| Premiums and discounts on available-for-sale marketable securities | (5,057) | (4,646) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (3,342) | (2,305) |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's stock-based comp?
- Kymera Therapeutics (KYMR) reported stock-based comp of $18.94M in Q2 2026.
- How has Kymera Therapeutics's stock-based comp changed year-over-year?
- Kymera Therapeutics's stock-based comp increased by 22.8% year-over-year, from $15.42M to $18.94M.
- What is the long-term trend for Kymera Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Kymera Therapeutics's stock-based comp has grown at a 24.5% compound annual growth rate (CAGR), from $24.97M to $59.9M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Kymera Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude